title: [Novel type of vaccine with a combination of Toll like receptor agonists--TLR 1/2, 4, 5/6, 9].
abstract: OBJECTIVE
  Proof of therapeutic efficacy of a novel type of vaccine with a combination of natural Toll like receptor agonists (TLR) 1/2, 4, 5/6, 9 in infectious and noninfectious human pathology.
  
  
  METHODS
  Immunovac-VP-4 vaccine, containing antigens of opportunistic microorganisms that are TLR 1/2, 4, 5/6, 9 ligands, was used for experiments and clinical trials.
  
  
  RESULTS
  Immunovac-VP-4 activates innate immunity by inducing maturation of dendritic cells with expression of costimulating molecules on their membrane (CD40+, CD80+, CD86+), terminal differentiation molecules--CD83+ and antigen-presenting molecules (MHC class I and II); activates proinflammatory (TNFalpha, IL-6) and regulatory (IL-12, INFgamma) cytokine synthesis that programs T-lymphocyte differentiation by Th1 pathway; increases cytotoxic activity of natural killer cells, inhibits melanoma B16 growth and Lewis lung carcinoma metastasis. Therapeutic effect of Immunovac-VP-4 was evident regardless of pathology by a significant decrease of quantity and severity of recidives, improvement of all clinical parameters, reduction of quantity of administered pharmaceutical preparations including antibiotics and glucocorticosteroids. The rate of intercurrent acute respiratory viral illnesses and their bacterial complications decreased. Immunovac-VP-4 therapy modified course of illness from severe into milder forms. Positive therapeutic effect was 69.2 - 100%.
  
  
  CONCLUSIONS
  High therapeutic effect of vaccine therapy is based on innate immunity activation by combining TLR agonists. Immunovac-VP-4 contains an optimal combination of natural TLR agonists that ensure high therapeutic effect in various nosological forms of infectious and noninfectious human pathology.
authors.forename: N B
authors.initials: NB
authors.lastname: Egorova
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: I M
authors.initials: IM
authors.lastname: Gruber
authors.forename: I B
authors.initials: IB
authors.lastname: Semenova
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhaĭlova
authors.forename: V V
authors.initials: VV
authors.lastname: Zverev
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D001249:Asthma / Q000628:therapy; D001428:Bacterial Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D006558:Herpes Genitalis / Q000628:therapy; D006801:Humans; D007113:Immunity, Innate; D016233:Immunotherapy, Active / Q000379:methods*; D020315:Latex Hypersensitivity / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology; D008545:Melanoma / Q000628:therapy; D051379:Mice; D012141:Respiratory Tract Infections / Q000628:therapy; D051193:Toll-Like Receptors / Q000819:agonists* / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D051193:Toll-Like Receptors; C088865:VP-4 vaccine; D017778:Vaccines, Combined